SPCC (Sharing Progress in Cancer Care) shared a post on LinkedIn:
“How can we translate complex tumour biology into everyday clinical care?
Join us for the sixth session of the Definitive Trial Project, a European Commission-funded clinical trial demonstrating how the HER2DX® diagnostic assay can personalise treatment decisions and improve quality of life for patients with early-stage HER2-positive breast cancer, without compromising outcomes.
Program:
HER2DX: biological bases – Francesco Schettini
HER2DX: clinical perspective – Marta González
Discussion and Q&A – Moderated by Aleix Prat
Access is free of charge, but registration is mandatory.
Funded by the European Union – Horizon Europe Grant Agreement No. 101136953.
Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or HADEA. Neither the European Union nor the granting authority can be held responsible for them.
This work has also received funding from the Swiss State Secretariat for Education, Research and Innovation (SERI).”
Other articles about SPCC on OncoDaily.